Skip to content

The clinical application of PainVision in postherpetic neuralgia

The clinical application of PainVision in postherpetic neuralgia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024248
Enrollment
Unknown
Registered
2019-07-02
Start date
2019-07-04
Completion date
Unknown
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postherpetic neuralgia

Interventions

Case series:Pulse therapy

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Has a clear history of acute herpes zoster, and the herpes zoster lesions subsided > 1 month; 2. Herpes zoster area in the T3-T12 dominating area; 3. Aged between 50-90 years old male and female; 4. The NRS score is greater than 4; 5. BMI 18-24 kg/m2; 6. Volunteer to participate in this study and informed consents have signed.

Exclusion criteria

Exclusion criteria: 1. PHN in other innervation areas; 2. Treatment of local severe skin lesions or infection; 3. Severe abnormal blood coagulation 4. Pregnant, pregnant and lactating women; 5. Drug allergy patients; 6. With non-PHN that may affect PHN pain assessment Sexual pain; 7. With neuromuscular junction disease such as myasthenia gravis; 8. With severe mental illness, alcohol addiction or drug abuse; 9. Refused to accept the treatment plan; 10. For various reasons can not complete the study.

Design outcomes

Primary

MeasureTime frame
numerical rating scal;pain degree;

Secondary

MeasureTime frame
Hospital Anxiety and Depression Scale, HADS;Self-Rating Scale of Sleep;The McGill Pain Questionnaire;Analgesic drug consumption;

Contacts

Public ContactWhen Shen

Affiliated Hospital of Xuzhou Medical University

shenwen670201@163.com+86 13815311266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026